The drug works in treating the castration-resistant prostate cancer by releasing targeted alpha-particle-emitting radiation into the bones which kill the cancer cells but inflict limited damage to the surrounding tissue.
Algeta has joined hands with German drug maker Bayer in marketing the drug to urologists and oncologists in the US. Bayer had filed the new drug application with the FDA and has exclusive marketing rights of the drug outside the US. Analysts predict that Xofigo could generate as much as $1.3 billion in sales annually.
Source: Medindia
